Equities research analysts predict that Atara Biotherapeutics Inc (NASDAQ:ATRA) will report earnings per share (EPS) of ($1.29) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings, with the lowest EPS estimate coming in at ($1.32) and the highest estimate coming in at ($1.27). Atara Biotherapeutics posted earnings per share of ($1.75) during the same quarter last year, which suggests a positive year-over-year growth rate of 26.3%. The business is scheduled to announce its next earnings report on Tuesday, February 25th.
According to Zacks, analysts expect that Atara Biotherapeutics will report full year earnings of ($5.45) per share for the current fiscal year, with EPS estimates ranging from ($5.63) to ($5.14). For the next year, analysts expect that the business will report earnings of ($4.76) per share, with EPS estimates ranging from ($5.60) to ($3.09). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($1.31) EPS for the quarter, beating analysts’ consensus estimates of ($1.40) by $0.09.
Hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Atara Biotherapeutics by 59.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,699 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 1,010 shares during the period. Tower Research Capital LLC TRC acquired a new position in shares of Atara Biotherapeutics during the third quarter valued at $40,000. Marshall Wace LLP acquired a new position in shares of Atara Biotherapeutics during the first quarter valued at $284,000. Bank of Montreal Can lifted its stake in shares of Atara Biotherapeutics by 81.1% during the second quarter. Bank of Montreal Can now owns 8,314 shares of the biotechnology company’s stock valued at $167,000 after acquiring an additional 3,723 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its stake in shares of Atara Biotherapeutics by 25.2% during the third quarter. Oppenheimer & Co. Inc. now owns 12,682 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 2,550 shares during the period.
Shares of NASDAQ ATRA traded down $0.96 during trading hours on Wednesday, reaching $15.03. The stock had a trading volume of 611,689 shares, compared to its average volume of 656,038. The business’s fifty day moving average is $15.64 and its two-hundred day moving average is $14.59. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.56 and a quick ratio of 9.56. The company has a market cap of $813.88 million, a price-to-earnings ratio of -2.46 and a beta of 2.07. Atara Biotherapeutics has a twelve month low of $10.38 and a twelve month high of $41.97.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Further Reading: How much money do you need to begin day trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.